120373-36-6 Usage
Description
Unoprostone, also known as Rescula, is a docosanoid (22-carbon atom) prostaglandin F2α analog marketed as the isopropyl ester. It is supplied as a 0.15% sterile ophthalmic solution and is used for various applications due to its unique properties.
Uses
Used in Ophthalmology:
Unoprostone is used as a protectant against retinal degeneration in S334ter rhodopsin mutant rats. It serves as a neuroprotective agent, helping to preserve the health and function of the retina and other neural tissues in the eye.
Used in Pharmaceutical Industry:
Unoprostone is used as an active pharmaceutical ingredient for the treatment of various eye conditions. Its unique properties make it a valuable compound in the development of ophthalmic solutions, providing relief and support for patients with different eye-related issues.
General Description:
Unoprostone (Rescula) is a 22-carbon atom prostaglandin F2α analog with neuroprotective properties. It is supplied as a 0.15% sterile ophthalmic solution and is used to protect against retinal degeneration and serve as a neuroprotective agent in the field of ophthalmology. The natural 15-position alcohol is oxidized to the ketone, which is expected to occur in vivo. Cautions and side effects are similar to those previously mentioned for other prostaglandin analogs.
Check Digit Verification of cas no
The CAS Registry Mumber 120373-36-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,3,7 and 3 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 120373-36:
(8*1)+(7*2)+(6*0)+(5*3)+(4*7)+(3*3)+(2*3)+(1*6)=86
86 % 10 = 6
So 120373-36-6 is a valid CAS Registry Number.
InChI:InChI=1/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6+/t18-,19-,20+,21-/m1/s1
120373-36-6Relevant articles and documents
Processes for the preparation of isomer free prostaglandins
-
Paragraph 0241; 0242, (2015/03/03)
Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R2, R3 and R4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.
Treatment of cataract with 15-keto-prostaglandin compounds
-
, (2008/06/13)
A compound for treatment of a cataract which is a 15-ketoprostaglandin compound.
